UNITED STATES
                SECURITIES AND EXCHANGE COMMISSION
                      Washington, D.C. 20549

                          FORM 10-KSB/A
                         Amendment No. 1

[X]   ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934

      For the fiscal year ended December 31, 2005

[ ]   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES
      AND EXCHANGE ACT OF 1934

                 Commission file number 000-32363

                       CANCER CAPITAL CORP.
       ----------------------------------------------------
      (Exact name of registrant as specified in its charter)

              Nevada                           91-1803648
       ----------------------    -----------------------------------
      (State of incorporation)   (I.R.S. Employer Identification No.)


2157 S. Lincoln Street, Salt Lake City, Utah            84106
---------------------------------------------           ------
(Address of principal executive offices)             (Zip code)

Issuer's telephone number, including area code: (801) 323-2395

Securities registered under Section 12(b) of the Exchange Act:  None

Securities registered under Section 12(g) of the Exchange Act:  Common Stock

Check whether the issuer is not required to file reports pursuant to Section
13 or 15(d) of the Exchange Act. [ ]

The issuer (1) filed all reports required to be filed by Section 13 or 15(d)
of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports) and
(2) has been subject to such filing requirements for the past 90 days.
Yes [X]  No [ ]

Disclosure of delinquent filers in response to item 405 of Regulation S-B is
not contained herein, and will not be contained, to the best of registrant's
knowledge, in definitive proxy or information statements incorporated by
reference in Part III of this Form 10-KSB or any amendment to this Form
10-KSB. [X]

Indicate by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Exchange Act).   Yes [X]   No [ ]

State issuer's revenue for its most recent fiscal year: None

As of February 23, 2006, the registrant had 6,150,000 shares of common stock
outstanding.  A market value of the voting stock held by non-affiliates can
not be determined because the registrant does not have an active trading
market.

Documents incorporated by reference: None.

Transitional Small Business Disclosure Format: Yes [ ] No [X]


<PAGE>

                         EXPLANATORY NOTE

In June 2006 the Securities and Exchange Commission ("SEC") conducted a
limited review of our annual report on Form 10-KSB for the year ended December
31, 2005.  The SEC requested that we revise the language in the auditor's
report provided by Chisholm, Bierwolf & Nilson, LLC, dated March 2, 2006,
which is included with the financial statements for the years ended December
31, 2005 and 2004.

                        TABLE OF CONTENTS

                              PART I

Item 1.  Description of Business............................................3
Item 2.  Description of Property............................................5
Item 3.  Legal Proceedings..................................................5
Item 4.  Submission of Matters to a Vote of Security Holders................5

                             PART II

Item 5.  Market for Common Equity and Related Stockholder Matters...........5
Item 6.  Management's Discussion and Analysis or Plan of Operation..........6
Item 7.  Financial Statements...............................................6
Item 8.  Changes In and Disagreements with Accountants on Accounting and
         Financial Disclosure..............................................16
Item 8A. Controls and Procedures...........................................16
Item 8B. Other Information.................................................16

                             PART III

Item 9.  Directors, Executive Officers, Promoters and Control Persons,
         Compliance with Section 16(a) of the Exchange Act.................16
Item 10. Executive Compensation............................................17
Item 11. Security Ownership of Certain Beneficial Owners and Management
        and Related Stockholder Matters...................................17
Item 12. Certain Relationships and Related Transactions....................18
Item 13. Exhibits..........................................................18
Item 14.  Principal Accountant Fees and Services...........................19
Signatures.................................................................20


In this annual report references to "Cancer Capital," "we," "us," and "our"
refer to Cancer Capitol Corp.

        SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

The Securities and Exchange Commission ("SEC") encourages companies to
disclose forward-looking information so that investors can better understand
future prospects and make informed investment decisions.  This report contains
these types of statements.  Words such as "may," "will," "expect," "believe,"
"anticipate," "estimate," "project," or "continue" or comparable terminology
used in connection with any discussion of future operating results or
financial performance identify forward-looking statements.  You are cautioned
not to place undue reliance on the forward-looking statements, which speak
only as of the date of this report.  All forward-looking statements reflect
our present expectation of future events and are subject to a number of
important factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.

                                2

<PAGE>


                              PART I

                 ITEM 1. DESCRIPTION OF BUSINESS

Historical Development

We were incorporated in the state of Nevada on April 11, 1997, to develop an
alternative medical waste treatment and processing equipment system.  We were
unsuccessful in our efforts and are inactive at this time.

Our Plan

We are a development stage company and have had recurring operating losses for
the past two fiscal years.  Our independent auditors have expressed doubt that
we can continue as a going concern unless we obtain financing to continue
operations.

Our business plan is to seek, investigate, and, if warranted, acquire an
interest in a business opportunity.  Our acquisition of a business opportunity
may be made by merger, exchange of stock, or otherwise.  We have very limited
sources of capital, and we probably will only be able to take advantage of one
business opportunity. As of thee date of this filing we have not identified
any business opportunity that we plan to pursue, nor have we reached any
preliminary or definitive agreements or understandings with any person
concerning an acquisition or merger.

Based on current economic and regulatory conditions, management believes that
it is possible, if not probable, for a company like ours, without many assets
or liabilities, to negotiate a merger or acquisition with a viable private
company.  The opportunity arises principally because of the expensive legal
and accounting fees and the length of time associated with the registration
process of "going public."  However, should any of these conditions change, it
is very possible that there would be little or no economic value for anyone
taking over control of Cancer Capital.

Our search for a business opportunity will not be limited to any particular
geographical area or industry and includes both U.S. and international
companies.  Our management has unrestricted discretion in seeking and
participating in a business opportunity, subject to the availability of such
opportunities, economic conditions and other factors.  Our management believes
that companies who desire a public market to enhance liquidity for current
stockholders or plan to acquire additional assets through issuance of
securities rather than for cash, will be potential merger or acquisition
candidates.

The selection of a business opportunity in which to participate is complex and
extremely risky and will be made by management in the exercise of its business
judgement.  Our activities are subject to several significant risks which
arise primarily as a result of the fact that we have no specific business and
may acquire or participate in a business opportunity based on the decision of
management which will, in all probability, act without consent, vote, or
approval of our stockholders.  We can not assure you that we will be able to
identify and acquire any business opportunity which will ultimately prove to
be beneficial to Cancer Capital and our stockholders.  Should a merger or
acquisition prove unsuccessful, it is possible management may decide not to
pursue further acquisition activities and management may abandon our search
and we may become dormant or be dissolved.

It is possible that the range of business opportunities that might be
available for consideration by us could be limited by the fact that our common
stock is not listed on any market.  We cannot assure you that a market will
develop or that a stockholder will be able to liquidate his/her/its
investments without considerable delay, if at all.  If a market develops, our
shares will likely be subject to the rules of the Penny Stock Suitability
Reform Act of 1990.  The liquidity of penny stock is affected by specific
disclosure procedures required by this Act to be followed by all
broker-dealers, including but not limited to, determining the suitability of
the stock for a particular customer, and obtaining a written agreement from
the customer to purchase the stock.  This rule may affect the ability of
broker-dealers to sell our securities and may affect the ability of purchasers
to sell our securities in any market.

                                3

<PAGE>


Investigation and Selection of Business Opportunities

We anticipate that business opportunities will come to our attention from
various sources, including our officers and directors, our stockholders,
professional advisors such as attorneys and accountants, securities
broker-dealers, investment banking firms, venture capitalists, members of the
financial community and others who may present unsolicited proposals.
Management expects that prior personal and business relationships may lead to
contacts with these various sources.

Our management will analyze the business opportunities; however, none of our
management are professional business analysts.  (See Part III, Item 9, below.)
Our management has had limited experience with acquisitions or mergers of
business opportunities and has not been involved with an initial public
offering.  Due to our management's inexperience with acquisitions and mergers,
they may rely on promoters or their affiliates, principal stockholders or
associates to assist in the investigation and selection of business
opportunities.

Certain conflicts of interest exist or may develop between Cancer Capital and
our officers and directors.  Our management has other business interests to
which they currently devote attention, which include their primary employment
and Mr. Peters is management of other development stage reporting companies
seeking merger candidates.  Our management may be expected to continue to
devote their attention to these other business interests although management
time should be devoted to our business.  As a result, conflicts of interest
may arise that can be resolved only through their exercise of judgement in a
manner which is consistent with their fiduciary duties to us.

A decision to participate in a specific business opportunity may be made upon
our management's analysis of:
..      the quality of the business opportunity's management and personnel,
..      the anticipated acceptability of its new products or marketing concept,
..      the merit of its technological changes,
..      the perceived benefit that it will derive from becoming a publicly held
       entity, and
..      numerous other factors which are difficult, if not impossible, to
       analyze through the application of any objective criteria.

No one factor described above will be controlling in the selection of a
business opportunity.  Management will attempt to analyze all factors
appropriate to each opportunity and make a determination based upon reasonable
investigative measures and available data.  Potential business opportunities
may occur in many different industries and at various stages of development.
Thus, the task of comparative investigation and analysis of such business
opportunities will be extremely difficult and complex.  Potential investors
must recognize that because of our limited capital available for investigation
and management's limited experience in business analysis, we may not discover
or adequately evaluate adverse facts about the business opportunity to be
acquired.

In many instances, we anticipate that the historical operations of a specific
business opportunity may not necessarily be indicative of the potential for
the future because of the possible need to substantially shift marketing
approaches, significantly expand operations, change product emphasis, change
or substantially augment management, or make other changes.  We will be
dependent upon the owners of a business opportunity to identify any such
problems which may exist and to implement, or be primarily responsible for,
the implementation of required changes.

Form of Acquisition

We cannot predict the manner in which we may participate in a business
opportunity. Specific business opportunities will be reviewed as well as our
needs and desires and those of the promoters of the opportunity.  The legal
structure or method deemed by management to be suitable will be selected based
upon our review and our relative negotiating strength. Such methods may
include, but are not limited to, leases, purchase and sale agreements,
licenses, joint ventures and other contractual arrangements. We may act
directly or indirectly through an interest in a partnership, corporation or
other forms of organizations.  We may be required to merge, consolidate or
reorganize with other corporations or forms of business organizations. In
addition, our present management and stockholders most likely will not have
control of a majority of our voting shares following a merger or
reorganization transaction. As part of such a transaction, our existing
directors may resign and new directors may be appointed without any vote by
our stockholders.


                                4

<PAGE>


We likely will acquire our participation in a business opportunity through the
issuance of common stock or other securities.  Although the terms of any such
transaction cannot be predicted, it should be noted that issuance of
additional shares also may be done simultaneously with a sale or transfer of
shares representing a controlling interest by current principal stockholders.

In the event we merge or acquire a business opportunity, the successor company
will be subject to our reporting obligations.  This is commonly referred to as
a "back door registration."  A back door registration occurs when a
non-reporting company becomes the successor of a reporting company by merger,
consolidation, exchange of securities, acquisition of assets or otherwise.
This type of event requires the successor company to file a current report
with the SEC which provides the same kind of information about the company to
be acquired that would appear in a registration statement, including audited
and pro forma financial statements.  Accordingly, we may incur additional
expense to conduct due diligence and present the required information for the
business opportunity in any report.  Also, the SEC may elect to conduct a full
review of the successor company and may issue substantive comments on the
sufficiency of disclosure related to the company to be acquired.

Competition

We expect to encounter substantial competition in our effort to locate
attractive opportunities.  Business development companies, venture capital
partnerships and corporations, venture capital affiliates of large industrial
and financial companies, small investment companies, and wealthy individuals
will be our primary competition. Many of these entities will have
significantly greater experience, resources and managerial capabilities than
we do and will be in a better position than we are to obtain access to
attractive business opportunities.  We also will experience competition from
other public development stage companies seeking merger candidates, many of
which may have more funds available for such transactions.

Employees

We currently have no employees.  Our management expects to confer with
consultants, attorneys and accountants as necessary.  We do not anticipate a
need to engage any full-time employees so long as we are seeking and
evaluating business opportunities.

                 ITEM 2. DESCRIPTION OF PROPERTY

We do not currently own or lease any property.  Until we pursue a viable
business opportunity and recognize income, we will not seek office space.

                    ITEM 3. LEGAL PROCEEDINGS

We are not a party to any proceedings or threatened proceedings as of the date
of this filing.

   ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

We have not submitted a matter to a vote of our shareholders during the fourth
quarter of the 2005 fiscal year.


                             PART II

ITEM 5: MARKET PRICE FOR COMMON EQUITY, RELATED STOCKHOLDER MATTERS

Market, Holders and Dividends

Our common stock is not listed on a public market as of the date of this
filing.  We have approximately 38


                                5

<PAGE>

stockholders of record holding 6,150,000 common shares.  We have not declared
dividends on our common stock and do not anticipate paying dividends on our
common stock in the foreseeable future.

Recent Sales of Unregistered Securities

None.

Issuer Purchase of Securities

None.

ITEM 6.  MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

We are a development stage company and have recorded losses since our
inception.  At December 31, 2005, we had $1,280 cash and total liabilities of
$14,750.  We cannot satisfy our cash requirements for our operations which are
related to legal, accounting and professional services required to prepare and
file our reports with the SEC.  We are unable to pay cash for these services
and have relied on related and third parties to pay for these costs on our
behalf.  These parties have not entered into written agreements guaranteeing
advances and, therefore, these parties are not obligated to provide funds in
the future.  However, management anticipates that these parties will continue
providing advances during the next twelve months.  Historically, we have paid
for these advances by converting the debt into common stock.

Our plan for the next twelve months is to search for a business opportunity
and, if feasible, acquire an interest in a business opportunity.  If we obtain
a business opportunity, then it may be necessary to raise additional capital.
We likely will sell our common stock to raise this additional capital.  We
expect to issue such stock pursuant to exemptions provided by federal and
state securities laws.  The purchasers and manner of issuance will be
determined according to our financial needs and the available exemptions.  We
do not currently intend to make a public offering of our stock.  We also note
that if we issue more shares of our common stock, then our shareholders may
experience dilution in the value per share of their common stock.


                   ITEM 7. FINANCIAL STATEMENTS






                       Cancer Capital Corp.

                  (A Development Stage Company)

                       Financial Statements

                    December 31, 2005 and 2004





                                6

<PAGE>






                             CONTENTS


Independent Auditor's Report .........................................8

Balance Sheets .......................................................9

Statements of Operations ............................................10

Statements of Stockholders' Equity ..................................11

Statements of Cash Flows ............................................12

Notes to the Financial Statements ................................13-15



                                7

<PAGE>



Chisholm                                        533 West 2600 South, Suite 25
Bierwolf &                                      Bountiful, Utah 84010
Nilson, LLC                                     Phone: (801) 292-8756
Certified Public Accountants                    Fax: (801) 292-8809


     REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders
of Cancer Capital Corp.:

We have audited the accompanying balance sheets of Cancer Capital Corp. (a
development stage company) as of December 31, 2005 and 2004 and the related
statements of operations, stockholders' equity and cash flows for the years
ended December 31, 2005 and 2004 and from inception April 11, 1997 through
December 31, 2005.  These financial statements are the responsibility of the
Company's management.  Our responsibility is to express an opinion on these
financial statements based on our audits.

We conducted our audits in accordance with the standards of the P.C.A.O.B.
(United States).  Those standards require that we plan and perform the audits
to obtain reasonable assurance about whether the financial statements are free
of material misstatement.  The Company is not required to have, nor were we
engaged to perform, an audit of its internal control over financial reporting.
Our audit included consideration of internal control over financial reporting
as a basis for designing audit procedures that are appropriate in the
circumstances, but not for the purpose of expressing an opinion on the
effectiveness of the Company's internal control over financial reporting.
Accordingly, we express no such opinion. An audit also includes examining, on
a test basis, evidence supporting the amounts and disclosures in the financial
statements, assessing the accounting principles used and significant estimates
made by management, as well as evaluating the overall financial statement
presentation.  We believe that our audits provide a reasonable basis for our
opinion.

In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Cancer Capital Corp.  (a
development stage company) as of December 31, 2005 and 2004 and the results of
its operations and cash flows for the years ended December 31, 2005 and 2004
and from inception April 11, 1997 through December 31, 2005 in conformity with
generally accepted accounting principles in the United States of America.

The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern.  The Company has suffered recurring
losses from operations which raises substantial doubt about its ability to
continue as a going concern.  Management's plans in regard to these matters
are described in Note 2.  The financial statements do not include any
adjustments that might result from the outcome of this uncertainty.


/s/ Chisholm, Bierwolf & Nilson

Chisholm, Bierwolf & Nilson
Bountiful, Utah 84010
March 2, 2006



                                8

<PAGE>



                       Cancer Capital Corp.
                  (A Development Stage Company)
                          Balance Sheets

                              ASSETS
                                                          December 31
                                                  ---------------------------
                                                        2005         2004
                                                  ------------- -------------
CURRENT ASSETS

Cash (Note 1)                                     $      1,280  $      3,706
                                                  ------------- -------------

  TOTAL ASSETS                                    $      1,280  $      3,706
                                                  ============= =============

               LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES

Accounts Payable - related party                  $      9,750  $      5,000
Accounts Payable - other                                 5,000         5,160
                                                  ------------- -------------

   Total Liabilities                                    14,750        10,160

STOCKHOLDERS' EQUITY

Common Stock, $.001 par value; 20,000,000
  shares authorized; 6,150,000 shares
  issued and outstanding                                 6,150         6,150

Additional Paid in Capital                              47,050        47,050

Deficit Accumulated during the development stage       (66,670)      (59,654)
                                                  ------------- -------------

   Total Stockholders' Equity (deficit)                (13,470)       (6,454)
                                                  ------------- -------------

   TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY     $      1,280  $      3,706
                                                  ============= =============



The accompanying notes are an integral part of these financial statements


                                9

<PAGE>


                       Cancer Capital Corp.
                  (A Development Stage Company)
                     Statements of Operations


                                                                From
                                                                Inception on
                                       For the years ended      April 11,
                                          December 31,          1997 to
                                    --------------------------- Dec. 31,
                                         2005         2004      2005
                                    ------------- ------------- -------------

REVENUES                            $          -  $          -  $          -
                                    ------------- ------------- -------------
EXPENSES
  General & Administrative                 7,016         2,070        59,654
                                    ------------- ------------- -------------

    Total Expenses                         7,016         2,070        59,654
                                    ------------- ------------- -------------

Net Loss                            $     (7,016) $     (2,070) $    (59,654)
                                    ============= ============= =============

Net Loss Per Share                  $      (0.00) $      (0.00) $      (0.01)
                                    ============= ============= =============

Weighted average shares outstanding    6,150,000     6,150,000     5,165,551
                                    ============= ============= =============






The accompanying notes are an integral part of these financial statements



                                10

<PAGE>



                       Cancer Capital Corp.
                  (A Development Stage Company)
                Statements of Stockholders' Equity
    From Inception on April 11, 1997 through December 31, 2005

                                                                 Deficit
                                                                 Accumulated
                                                     Additional  During the
                                Common Stock         Paid in     Development
                             Shares       Amount     Capital     Stage
                           ------------- ----------- ----------- -------------
Common stock, issued at
 inception for cash at
 $.001 per share              1,000,000  $    1,000  $        -  $          -

Common stock, issued at
 inception for services
 at $.001 per share             200,000         200           -             -

Common stock issued for
 cash at $.01 per share       3,500,000       3,500      31,500             -

Net (loss) for the year
 ended December 31, 1997              -           -           -       (22,400)
                           ------------- ----------- ----------- -------------
Balance - December 31, 1997   4,700,000       4,700      31,500       (22,400)

Net (loss) for the year
 ended December 31, 1998              -           -           -        (9,900)
                           ------------- ----------- ----------- -------------
Balance - December 31, 1998   4,700,000       4,700      31,500       (32,300)

Net (loss) for the year
 ended December 31, 1999              -           -           -        (1,300)
                           ------------- ----------- ----------- -------------
Balance - December 31, 1999   4,700,000       4,700      31,500       (33,600)

Common stock issued for
 services at $.01 per share     200,000         200       1,800             -

Common stock issued for
 services at $.02 per share     250,000         250       4,750             -

Net (loss) for the year
 ended December 31, 2000              -           -           -        (7,600)
                           ------------- ----------- ----------- -------------
Balance - December 31, 2000   5,150,000       5,150      38,050       (41,200)

Net (loss) for the year
 ended December 31, 2001              -           -           -             -
                           ------------- ----------- ----------- -------------
Balance - December 31, 2001   5,150,000       5,150      38,050       (41,200)

Net (loss) for the year
 ended December 31, 2002              -           -           -        (5,139)
                           ------------- ----------- ----------- -------------
Balance - December 31, 2002   5,150,000       5,150      38,050       (46,339)

Common stock issued for
 services at $.01 per share   1,000,000       1,000       9,000             -

Net (loss) for the year
  ended December 31, 2003             -           -           -       (11,245)
                           ------------- ----------- ----------- -------------
Balance - December 31, 2003   6,150,000       6,150      47,050       (57,584)

Net (loss) for the year
  ended December 31, 2004             -           -           -        (2,070)
                           ------------- ----------- ----------- -------------
Balance - December 31, 2004   6,150,000       6,150      47,050       (59,654)
(59,654)

Net (loss) for the year
 ended December 31, 2005              -           -           -        (7,016)
                           ------------- ----------- ----------- -------------

Balance - December 31, 2005   6,150,000  $    6,150  $   47,050  $    (66,670)
                           ============= =========== =========== =============



The accompanying notes are an integral part of these financial statements


                               -11

<PAGE>

                       Cancer Capital Corp.
                  (A Development Stage Company)
                     Statements of Cash Flows
                                                                From
                                                                Inception on
                                       For the years ended      April 11,
                                          December 31,          1997 through
                                    --------------------------- December 31,
                                         2005         2004      2005
                                    ------------- ------------- -------------
Cash Flows from Operating Activities

  Net Loss                          $     (7,016) $     (2,070) $    (66,670)
  Adjustments for non-cash items:
   Increase in Accounts Payable            4,590         5,160        14,750
   Shares issued for services                  -             -        17,200
                                    ------------- ------------- -------------
   Net Cash Provided (Used)
    by Operating Activities               (2,426)        3,090       (34,720)
                                    ------------- ------------- -------------

Cash Flows from Investing Activities           -             -             -
                                    ------------- ------------- -------------
   Net Cash Provided (Used)
    in Investing Activities                    -             -             -
                                    ------------- ------------- -------------
Cash Flows from Financing Activities
  Issued common stock for cash                 -             -        36,000
                                    ------------- ------------- -------------
  Net cash Provided by
   Financing Activities                        -             -        36,000
                                    ------------- ------------- -------------

Increase (Decrease) in Cash               (2,426)        3,090         1,280

Cash - beginning of period                 3,706           616             -
                                    ------------- ------------- -------------

Cash - end of period                $      1,280  $      3,706  $      1,280
                                    ============= ============= =============

Supplemental Cash Flow Information:

  Cash Paid For:
    Interest                        $          -  $          -  $          -
    Income Taxes                    $          -  $          -  $          -

Non-Cash Financing Activities

  During 1997, 200,000 shares of common stock were issued at $.001 per share
  for services

  During 2000, 200,000 and 250,000 shares of common stock were issued for
  services at $.01 and $.02 per share, respectively

  During 2003, 1,000,000 shares of common stock were issued for services at
  $.01 per share

The accompanying notes are an integral part of these financial statements

                               -12


<PAGE>


                       Cancer Capital Corp.
                  (A Development Stage Company)
                Notes to the Financial Statements
                    December 31, 2005 and 2004

NOTE 1 - Summary of Significant Accounting Policies

     a.  Organization & Consolidation Policy

         Cancer Capital Corp.  (the Company), was incorporated April 11, 1997
under the laws of the State of Nevada.   The Company was originally formed for
the purpose of developing an alternative medical waste treatment system.
However, the Company in December 1997 abandoned this purpose and has since
been inactive.  The Company has never commenced any significant activities or
secured operations.  The Company is currently searching for other business
opportunities and is in the development stage according to Financial
Accounting Standards Board Statement No. 7.

     b.  Accounting Method

         The Company recognizes income and expense on the accrual basis of
accounting.

     c.  Earnings (Loss) Per Share


                                         Income (loss)   Shares      Per Share
                                         (Numerator)  (Denominator)   Amount
                                        ------------- ------------- ----------
For the year ended December 31, 2005:

  Basic EPS
  Income (loss) to common stockholders  $     (2,070)   _6,150,000  $   (0.00)
                                        ============= ============= ==========
For the year ended December 31, 2004:

  Basic EPS
  Income (loss) to common stockholders  $     (2,070)    6,150,000  $   (0.00)
                                        ============= ============= ==========
From inception on April 11, 1997 to
December 31, 2005:

  Basic EPS
  Income (loss) to common stockholders  $    (66,670)    5,161,551  $   (0.01)
                                        ============= ============= ==========

         The computation of earnings per share of common stock is based on the
weighted average number of shares outstanding at the date of the financial
statements.

     d.  Cash and Cash Equivalents

         The Company considers all highly liquid investments with maturities
of three months or less to be cash equivalents.


                                13

<PAGE>



                       Cancer Capital Corp.
                  (A Development Stage Company)
                Notes to the Financial Statements
                    December 31, 2005 and 2004

NOTE 1 - Summary of Significant Accounting Policies (continued)

     e.  Provision for Income Taxes

         No provision for income taxes have been recorded due to net operating
loss carryforwards totaling $66,670 which will be offset against future
taxable income.  These NOL carryforwards began to expire in the year 2017  No
tax benefit has been reported in the financial statements because the Company
believes there is a 50% or greater chance the carryforward will expire unused.

         Deferred tax asset and the valuation account is as follows as
December 31, 2005 and 2004:
                                                         December 31,
                                                      2005          2004
                                                 -------------- -------------
      Deferred tax asset:
          NOL carryforward                       $      22,668  $     20,282
          Valuation allowance                          (22,668)      (20,282)
                                                 -------------- -------------
                                                 $           -  $          -
                                                 ============== =============

     f.  Use of estimates

         The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period.  Actual results could differ from those estimates.

NOTE 2 - Going Concern

         The accompanying financial statements have been prepared assuming
that the Company will continue as a going concern.  The Company has minimal
assets and has had recurring operating losses for the past several years and
is dependent upon financing to continue operations.  The financial statements
do not include any adjustments that might result from the outcome of this
uncertainty.  It is management's plan to find an operating company to merge
with, thus creating necessary operating revenue.

NOTE 3 - Development Stage Company

         The Company is a development stage company as defined in Financial
Accounting Standards Board Statement No. 7.  It is concentrating substantially
all of its efforts in raising capital and defining its business operation in
order to generate significant revenues.


                                14

<PAGE>


                       Cancer Capital Corp.
                  (A Development Stage Company)
                Notes to the Financial Statements
                    December 31, 2005 and 2004

NOTE 4 - Related Party Transactions

         As of the year ended December 31, 2004, the Company has incurred
$5,000 of professional fees payable to professionals affiliated with First
Equity Holdings Corp.  An officer of the Company is also an employee of First
Equity Holdings Corp.

         As of the year ended December 31, 2005, the Company has incurred
$4,750 of professional fees payable to professionals affiliated with First
Equity Holdings Corp.  An officer of the Company is also an employee of First
Equity Holdings Corp.


NOTE 5 - Stockholders' Equity

         In 1997 the Company issued 1,000,000 shares of common stock for cash
of $1,000 ($.001 per share).  It issued 200,000 shares of stock for services
valued at $200.  It also issued 3,500,000 shares for cash of $35,000 ($.01 per
share).

         In 2000  the Company issued 200,000 shares of stock for services
valued at $2,000.  It also issued 500,000 shares of stock for services valued
at $10,000.

         During 2003, the Company issued 1,000,000 shares of common stock, for
services valued at $10,000 (or $.01 per share).


                                15





<PAGE>



      ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
              ON ACCOUNTING AND FINANCIAL DISCLOSURE

In our current report dated February 9, 2004, we reported that our independent
auditors, Chisholm & Associates, Certified Public Accountants, resigned as our
independent auditors and we engaged Chisholm, Bierwolf & Nilson, LLC,
Certified Public Accountants, as our independent auditors .

                ITEM 8A.  CONTROLS AND PROCEDURES

Our President, who acts in the capacities of our principal executive officer
and principal financial officer, evaluated the effectiveness of our disclosure
controls and procedures as of the end of the period covered by this report.
Based on that evaluation, he concluded that our disclosure controls and
procedures were effective.

He also determined that there were no changes made in our internal controls
over financial reporting during the fourth quarter of 2005 that have
materially affected, or are reasonably likely to materially affect our
internal control over financial reporting.

                    ITEM 8B. OTHER INFORMATION

None.



                             PART III

ITEM 9. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS,
        COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT

Directors and Officers

Our executive officers and directors and their respective ages, positions and
biographical information are set forth below.  Our bylaws require two
directors who serve for terms of one year or until they are replaced by a
qualified director.  Our executive officers are chosen by our board of
directors and serve at its discretion.  John and Michelle Peters are married.

Name               Age     Position Held                    Director Since
-------------     -------  ---------------                  --------------
John W. Peters      54     President and Director               April 1997
L. Michelle Peters  53     Secretary/Treasurer and Director     April 1997

John W. Peters:  Since July 1999 Mr. Peters has been the manager of
Development Specialties, Inc. a property management company.  Since 1995 to
the present he has been President and Chairman of the Board of Earth Products
and Technologies, Inc, a reporting company.  Prior to 1995 he was employed as
Earth Products' operations manager.  He also is a director of Bingham Canyon
Corporation, Skinovation Pharmaceutical Incorporated and Suncrest Global
Energy Corp., which are development stage reporting companies.  His prior
business experience includes President and Executive Officer of Certified
Environmental Laboratories, Inc. and Vice President of Sales and Marketing for
Comco Communications Corp. in California.  Mr. Peters studied business
administration at Long Beach Community College and California Polytechnic
State University in San Louis Obispo, California.

L. Michelle Peters:  Mrs. Peters has served as our Secretary/Treasurer and as
a Director since our inception.  She is a representative of ForeverGreen
International, LLC, a Utah limited liability company which is a network
marketing company focused on whole foods and natural products.  Prior to 2005
she was a legal secretary for law firms located in Salt Lake City, Utah.  She
has over 30 years of experience in the legal profession as a legal secretary,
paralegal and office administrator.


                                16


<PAGE>

Audit Committee Financial Expert

Because we have minimal operations we do not have an audit committee serving
at this time, nor do we have an audit committee financial expert serving on an
audit committee.

Compliance with Section 16(a) of the Exchange Act

Section 16(a) of the Securities Exchange Act of 1934 requires our directors,
executive officers and persons who own more than ten percent of a registered
class of our equity securities, to file with the Securities and Exchange
Commission initial reports of ownership and reports of changes in ownership of
our common stock.  Officers, directors and greater than ten-percent beneficial
owners are required by SEC regulations to furnish us with copies of all
Section 16(a) reports they file.  We believe no filings were required to be
filed during 2005.

Code of Ethics

Due to the fact that we have minimal operations, we have not adopted a code of
ethics for our principal executive and financial officers.  Our board of
directors will revisit this issue in the future to determine if adoption of a
code of ethics is appropriate.  In the meantime, our management intends to
promote honest and ethical conduct, full and fair disclosure in our reports to
the SEC, and compliance with applicable governmental laws and regulations.

                 ITEM 10. EXECUTIVE COMPENSATION

Our named executive officers have not received any cash compensation, bonuses,
stock appreciation rights, long term compensation, stock awards or long-term
incentive rights in excess of $100,000 during the past three fiscal years.
John W. Peters, who acts in the capacity similar to chief executive officer
did not receive any compensation during the year ended December 31, 2005.  We
have not entered into employment contracts with our executive officers and
their compensation, if any, will be determined at the discretion of our Board
of Directors.

Compensation of Directors

We do not have any standard arrangement for compensation of our directors for
any services provided as director, including services for committee
participation or for special assignments.

ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
                 AND RELATED STOCKHOLDER MATTERS

Securities Under Equity Compensation Plans

We do not have any securities authorized for issuance under any equity
compensation plans.

Beneficial Ownership

The following table sets forth the beneficial ownership of our outstanding
common stock by our management and each person or group known by us to own
beneficially more than 5% of our outstanding common stock.  Beneficial
ownership is determined in accordance with the rules of the SEC and generally
includes voting or investment power with respect to securities.  Except as
indicated by footnote, the persons named in the table below have sole voting
power and investment power with respect to all shares of common stock shown as
beneficially owned by them.  The percentage of beneficial ownership is based
upon 6,150,000 shares of common stock outstanding as of February 23, 2006.




                                17

<PAGE>



                    CERTAIN BENEFICIAL OWNERS

Name and Address of              Number of Shares of
Beneficial Owners                Common Stock             Percentage of Class
------------------------         -------------------      -------------------

Compass Equity Partners               500,000                  8.1%
369 East 900 South
Salt Lake City, Utah 84111

First Equity Holdings Corp.           500,000                  8.1%
2157 S. Lincoln Street
Salt Lake City, UT 84106

M. Jeanne Ball                        400,000                  6.5%
6071 Aries Drive
Salt Lake City, Utah 84118

Anita Patterson                       400,000                  6.5%
588 NO West Capital
Salt Lake City, Utah 84103


                            MANAGEMENT

Name and Address of               Number of Shares of
Beneficial Owners                 Common Stock             Percentage of Class
------------------------         ---------------------     -------------------
John W. Peters                        650,000                 10.6%
2157 S. Lincoln Street
Salt Lake City, Utah 84106

L. Michelle Peters                    450,000                  7.3%
2157 S. Lincoln Street
Salt Lake City, Utah 84106

All executive officers
and directors as a group            1,100,000                 17.9%




          ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

We have not engaged in any transactions in excess of $60,000 during the past
two years involving our executive officers, directors, 5% or more stockholders
or immediate family members of such persons.

                        ITEM 13. EXHIBITS

No.     Description
----    -----------
3.1     Articles of Incorporation (Incorporated by reference to exhibit 3.1 of
        Form 10-SB, filed September 18, 2000)
3.2     Bylaws of  Bingham Canyon (Incorporated by reference to exhibit 3.3 of
        Form 10-SB, filed September 18, 2000.
31.1    Principal Executive Officer Certification
31.2    Principal Financial Officer Certification
32.1    Section 1350 Certification



                                18

<PAGE>


         ITEM 14.  PRINCIPAL ACCOUNTANT FEES AND SERVICES


Accountant Fees

The following table presents the aggregate fees billed for each of the last
two fiscal years by our principal accountant, Chisholm, Bierwolf & Nilson LLC,
Certified Public Accountants, in connection with the audit of our financial
statements and other professional services rendered by that firm.

                                           2005          2004
                                       ----------     ---------
     Audit fees                        $    1,562     $   1,352
     Audit-related fees                         0             0
     Tax fees                                   0             0
     All other fees                    $        0     $       0

Audit fees represent the professional services rendered for the audit of our
annual financial statements and the review of our financial statements
included in quarterly reports, along with services normally provided by the
accountant in connection with statutory and regulatory filings or engagements.
Audit-related fees represent professional services rendered for assurance and
related services by the principal accountant that are reasonably related to
the performance of the audit or review of our financial statements that are
not reported under audit fees.

Tax fees represent professional services rendered by the principal accountant
for tax compliance, tax advice, and tax planning.  All other fees represent
fees billed for products and services provided by the principal accountant,
other than the services reported for the other categories.

Pre-approval Policies

We do not have an audit committee currently serving and as a result our board
of directors performs the duties of an audit committee.  Our board of
directors will evaluate and approve in advance the scope and cost of the
engagement of an auditor.  We do not rely on pre-approval policies and
procedures.

                                19

<PAGE>

                            SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.


Date: June 30, 2006                CANCER CAPITAL CORP.


                                   /s/ John W. Peters
                               By: _______________________________
                                   John W. Peters
                                   President





In accordance with the Exchange Act, this report has been signed below by the
following person on behalf of the registrant and in the capacities and on the
dates indicated.



                                /s/ John W. Peters
Date: June 30, 2006             ______________________________________
                                John W. Peters
                                Principal Executive Officer
                                Principal Financial and Accounting Officer



                                /s/ L. Michelle Peters
Date: June 30, 2006             _______________________________________
                                L. Michelle Peters
                                Secretary/Treasurer and Director


                                20